Day Two

• Discussing opportunities for post pandemic preparedness
• Harnessing vaccine stockpile technology
• Demonstrating mobile manufacturing systems

• Outline a strategy for global health R&D with end-to-end approach
• Explore a commitment for global health access with focus on health equity for infectious disease in low- and middle-income countries (LMICs)
• Discuss the scope of R&D funding support and upcoming opportunities for global health R&D

With organizations such as the Korean Disease Control and Prevention Agency (KDCA), the Korean Ministry of Health, and The RIGHT Foundation, driving investment into next-generation mRNA technologies, collaboration between Korean and international stakeholders to achieve success has never been more critical. They will also be key to advancing regional manufacturing capabilities and ensuring equitable access to vaccines worldwide, particularly across low- and middle-income countries (LMICs).

Hear from vaccine experts as they shed light on strategies to overcome the next pandemic through RNA technology innovations including:

• How to develop key biopharma partnerships to achieve the impact on global vaccine equity?
• How to leverage best practices for mRNA vaccine R&D and local manufacturing in LMICs?
• Outlining current bottlenecks with scaling up to ensure regional capacity and global availability of mRNA vaccines

This networking session is your opportunity to get face-to-face with many of the brightest minds working in the mRNA, cell and gene fields and establish meaningful business relationships.

• Exploring immunogenicity and protective efficacy of a next-generation self-amplifying RNA COVID-19 vaccine candidate
• Discussing biodistribution and nonclinical safety assessment supporting preclinical development
• Unveiling CMC development and process optimization toward clinical translation

• Outlining GC Biopharma’s mRNA Platform technology for better performance
• Showcasing next-generation mRNA constructs with proprietary patent-secured sequences, circular RNA and self-amplifying mRNA
• Discovering versatile applications of mRNA vaccines and therapeutics

• Overview of Eisai’s linear mRNA discovery platform
• Explore key advancements in stability and translation efficiency optimization
• Assess the platform potential and future directions for RNA technologies

• Unveil an update of EPDegTM bioPROTAC development
• Discuss the proved differentiating points of bioPROTAC platform from others
• Learn the current challenges and future directions

• Explore ON- and OFF-translational control using endogenous microRNAs as organ- and cell- specific markers
• Outline design principles for specific translation based on RNA Switch™ technology
• Discover immune cell–selective translation enabled by RNA Switches and its applications